Brief: Humanigen And Chime Biologics Enter Into Manufacturing Agreement For Covid-19 Therapeutic Candidate Lenzilumab

Humanigen

17/05/2021 13:50

May 17 (Reuters) - Humanigen Inc  HGEN.O :
    * HUMANIGEN AND CHIME BIOLOGICS ENTER INTO MANUFACTURING
AGREEMENT
FOR COVID-19 THERAPEUTIC CANDIDATE LENZILUMAB
    * HUMANIGEN INC - CHIME WILL USE KUBIO (CYTIVA) BIOLOGICS
FACILITY
IN CHINA
    * HUMANIGEN INC - COMMERCIAL PRODUCT IS PLANNED TO BE
AVAILABLE IN
2022

Source text for Eikon:  ID:nBw4gvlLva 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))